{"DataElement":{"publicId":"2186015","version":"1","preferredName":"Previous Cancer Identified Ind-2","preferredDefinition":"the yes/no indicator whether a previous or concurrent cancer has been identified.","longName":"PREV_CA_IDENT_IND2","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2186014","version":"1","preferredName":"Cancer Identified","preferredDefinition":"information related to a cancer being identified.","longName":"CA_IDENT","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177129","version":"1","preferredName":"Cancer","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","longName":"Cancer","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7A3A-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177529","version":"1","preferredName":"Identified","preferredDefinition":"Identified; having the identity known or established.","longName":"Identified","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Identification","conceptCode":"C25737","definition":"The procedure of having an identity established.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-520A-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFE92718-239C-6D18-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"},{"publicId":"6540049","version":"1","longName":"SSPedi (Symptom Screening in Pediatrics)","context":"COG"}]},{"publicId":"3029677","version":"1","longName":"UAMS Clinical Research","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812848","version":"1","longName":"UAMS New CDEs","context":"NCIP"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104941","version":"1","longName":"GOG-0281","context":"NRG"},{"publicId":"10000705","version":"1","longName":"GOG-0281","context":"NRG"}]},{"publicId":"5999742","version":"1","longName":"CRF CDEs","context":"CITN","ClassificationSchemeItems":[{"publicId":"5999747","version":"1","longName":"Eligibility CDEs","context":"CITN"}]}],"AlternateNames":[{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"PREV_CA_IDENT_IND2","type":"USED_BY","context":"NRG"},{"name":"PREV_CA_IDENT_IND2","type":"USED_BY","context":"CITN"},{"name":"Theradex","type":"USED_BY","context":"Theradex"},{"name":"ABTC","type":"USED_BY","context":"ABTC"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Previous or concurrent malign","type":"Preferred Question Text","description":"Previous or concurrent malignancy","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"No concurrent or previous invasive pelvic malignancy (cervical, uterine and rectal) within five years prior to registration.","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"No concurrent or previous malignancy within five years prior to registration","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"No prior invasive malignancy, unless disease-free for >= 5 years (Exceptions: non-melanoma skin cancer, in-situ cancers)","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Does the patient have any concurrent malignancies","url":null,"context":"CTEP"},{"name":"CRF Text5","type":"Alternate Question Text","description":"No concurrent second malignancy requiring systemic therapy","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Patients with a history of non-breast malignancies are eligible if they have remained disease-free for 5 years since completing their initial treatment regimen and are deemed by their physician to be at low risk for recurrence","url":null,"context":"CTEP"},{"name":"CRF Text6","type":"Alternate Question Text","description":"Does the patient have a previous or current malignancy at other sites, with the exception of curatively treated local tumors such as carcinoma-in-situ of the cervix, basal or squamous cell carcinoma of the skin, or tumors for which no relapse has been observed within 5 years?","url":null,"context":"CTEP"},{"name":"coexist","type":"Alternate Question Text","description":"Co-existing cancer types, or history of other cancer types","url":null,"context":"NCIP"},{"name":"CRF Text 7","type":"Alternate Question Text","description":"Does the patient have a co-existing or prior invasive malignancy(except from the primary tumor site or non-melanomatous skin cancer) unless disease free for a minimum of 3 years","url":null,"context":"CTEP"},{"name":"CRF Text 8","type":"Alternate Question Text","description":"History of prior malignancy within the past 5 years other than surgically cured non-melanoma skin cancer or cervical carcinoma in-situ","url":null,"context":"CTEP"},{"name":"CRF Text 11","type":"Alternate Question Text","description":"Has a known additional malignancy that is progressing or requires active treatment.  Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.","url":null,"context":"CTEP"},{"name":"CRF Text 9","type":"Alternate Question Text","description":"Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy","url":null,"context":"CTEP"},{"name":"CRF Text 10","type":"Alternate Question Text","description":"Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy","url":null,"context":"CTEP"},{"name":"ABTC Question Text","type":"Alternate Question Text","description":"Has the patient had a prior malignancy within the past 5 years?","url":null,"context":"ABTC"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Does patient have known history of (1) a different prior cancer diagnosis or (2) a concurrent cancer diagnosis?","url":null,"context":"Theradex"},{"name":"CRF test1","type":"Alternate Question Text","description":"Does patient have a concomitant or prior invasive malignancy?","url":null,"context":"NRG"},{"name":"CRF_Text_4","type":"Alternate Question Text","description":"Does the patient have history of invasive rectal malignancy, regardless of disease-free interval?","url":null,"context":"CTEP"},{"name":"CRF_Text_12","type":"Alternate Question Text","description":"Does the patient have previous or concurrent history of malignancies within 5 years prior to study treatment?","url":null,"context":"CTEP"},{"name":"CRF Text 12","type":"Alternate Question Text","description":"Did the patient have previous contralateral invasive breast cancer treated with anti-cancer therapy","url":null,"context":"CTEP"},{"name":"CITN-1","type":"Alternate Question Text","description":"Patient has a known additional malignancy that is progressing or requires active treatment.  Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.","url":null,"context":"CITN"},{"name":"ABTC-1603 Question Text","type":"Alternate Question Text","description":"Has the patient had a prior malignancy within the past 2 years?","url":null,"context":"ABTC"},{"name":"NRG CRF_Text2","type":"Alternate Question Text","description":"Does the patient have a prior history of ovarian cancer, including low malignant potential neoplasms (LMP), primary peritoneal carcinoma or fallopian tube carcinoma?","url":null,"context":"NRG"},{"name":"CRF Text 14","type":"Alternate Question Text","description":"Does the natural history or treatment of the prior or concurrent malignancy have the potential to interfere with the safety or efficacy assessment of the investigational regimen?","url":null,"context":"CTEP"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Does patient have additional malignancy diagnosed less than 2 years prior to enrollment that was treated with curative intent excluding non-melanoma skin cancer?","url":null,"context":"COG"},{"name":"CRF Text 13","type":"Alternate Question Text","description":"Does the patient have a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen?","url":null,"context":"CTEP"},{"name":"NRG_CRFTEXT_3","type":"Alternate Question Text","description":"Any history or current diagnosis of AML/MDS?","url":null,"context":"NRG"},{"name":"COG CRF Text 15","type":"Alternate Question Text","description":"Does history of additional malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast) unless untreated and stable or disease free for at least 3 years?","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Does patient have a history of additional malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast) unless untreated and stable or disease free for at least 3 years?","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFE927FB-5BCC-6EA7-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-23","modifiedBy":"GDEEN","dateModified":"2023-08-07","changeDescription":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw 03-20-2018 Removed upside down question mark from beginning of CRF Text 9 - DW","administrativeNotes":"2023.8.2 AQT added per ticket request CADSR0002682. ak","unresolvedIssues":null,"deletedIndicator":"No"}}